ambergen.com
AmbergenGenomic Cancer Signature Discovery. A new approach to proteomics and biomarker discovery. High-sensitivity mass spec-based mutation scanning. Rapid photocleavable compounds for biotechnology. A new form of ELISA based on proprietary cell-free expressed antigens. AmberGen secures $600K to develop allergy test on Illumina's BeadXpress platform. AmberGen and Mass General license novel autoantigen biomarkers to INOVA Diagnostics. For general purchasing, including PC-Biotin reagents, please contact sales at.
http://www.ambergen.com/